Diabetes News

The FDA is warning providers and patients that dosing errors with compounded injectable semaglutide may be leading to adverse events, according to a press release.

There are many important factors primary care providers must consider when prescribing popular anti-obesity medications, according to experts.

A voluntary medical device correction has been issued for a small number of continuous glucose monitoring sensors distributed in the first half of May, according to an industry press release.

Changing in-hospital nutritional insulin administration from before meals to after meals lowered hypoglycemia rates at a community hospital, according to study findings published in Diabetes Research and Clinical Practice.

An immunotherapy to treat type 1 diabetes for people with the human leukocyte antigen DR3-DQ2 genotype received its second fast-track designation from the FDA, according to a company press release.

Women with polycystic ovary syndrome and high androgen levels may have a higher risk for liver disease than those with PCOS and normal androgen levels, according to an analysis of UK Biobank data.

Individuals who develop type 1 diabetes during childhood experienced greater risk for several mental health conditions later in life, including anxiety disorders and substance use disorders, study results showed.

New prescriptions of GLP-1 receptor agonists for the treatment of obesity have increased significantly among individuals without type 2 diabetes in the last decade, according to a study in Annals of Internal Medicine.

In a single-center cohort of patients with heart failure and obesity, weight-loss surgery led to improved clinical outcomes including reduced BMI and HbA1c and less reliance on diuretics, researchers reported.

Semaglutide was not associated with increased risks for adverse neurologic or psychological disorders at 1 year compared with other diabetes drugs, according to data published in eClinicalMedicine.